Related Experiment Video
Updated: Aug 29, 2025
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
599
Thyroid carcinoma associated with other primary neoplasms, a single center study
Katalin Gabora1, Ovidiu Bălăcescu2, Adrian Trifa3
1Doctoral School of the Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Medicine and Pharmacy Reports
|September 5, 2022
Summary
Thyroid cancer patients have a higher risk of developing secondary primary cancers. The BRAF V600E mutation is a prognostic factor but does not predict these additional cancers.
Area of Science:
- Oncology
- Genetics
- Endocrinology
Background:
- Thyroid carcinoma is the most common endocrine malignancy, with increasing incidence.
- Patients with thyroid cancer have a higher risk of developing a second primary malignancy.
- The BRAF V600E mutation's role in associated neoplasms is under investigation.
Purpose of the Study:
- To investigate the association between thyroid carcinoma and other primary neoplasms.
- To determine the role of the BRAF V600E mutation in patients with multiple primary cancers.
Main Methods:
- Evaluation of patients with thyroid carcinoma and other malignancies (breast, colorectal, lung, melanoma).
- Genetic testing for the BRAF V600E mutation on paraffin-embedded tumor samples.
- Analysis of time intervals between diagnoses of primary neoplasms.
Main Results:
- 17 patients with thyroid carcinoma and associated primary malignancies were identified.
- Breast cancer was the most common associated primary tumor.
- BRAF V600E mutation positivity rate was 26.9% in tested patients, with most associations being metachronous.
Conclusions:
- The BRAF V600E mutation is a significant prognostic factor for neoplasms studied.
- BRAF V600E mutation status does not predict the development of metachronous or synchronous associated primary neoplasms in thyroid cancer patients.
